Johnson & Johnson JNJ

$260.99 +4.51 (1.76%)

Valuation

Market cap
613,993,792,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.46
Forward PE
22.08
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
2,209,472
Avg volume
6,615,530
Day's range
$254.99 – $261.39
Shares out
2,409,898,000
Stochastic %K
23%
Beta
0.21
Analysts
Strong Sell
Price target
$282.60

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

parcha Oct 9, 3:35 PM
https://www.cnbc.com/investingclub/2026/10/09/jim-cramers-top-10-things-to-watch-in-the-stock-market-friday.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension $LLY $JNJ Bank of America is all over the map on Club drug stocks. Price target cut on buy-rated Eli Lilly. PT raise on hold-rated Johnson & Johnson. The analysts tweaked their estimates for the industry ahead of earnings.
0 replies
Manny007 Oct 9, 12:37 PM
$JNJ $270-$280 next week
0 replies
focafoca99 Oct 9, 11:10 AM
$JNJ demonstrated robust 2-year Phase 3 data for ICOTYDE, with ~72% of patients achieving PASI 90 and ~44% reaching PASI 100. https://www.rapidticker.com/news/jnj-new-johnson-johnson-icotyde-icotrokinra-8c8e37
0 replies
flychicken1991 Oct 9, 11:05 AM
$JNJ New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis. Impact: Positive (82%). JNJ's stock receives light upward valuation support from reduced uncertainty about ICOTYDE's treatment durability and its potential to sustain psoriasis revenue; the evidence establishes no dilution pressure. Source and what to watch next: https://nimpact.tech/newsimpact/news/15a7ecc76c6dbf7f/jnj-new-johnson-johnson-icotyde-icotrokinra-long-term-data-demonstrate-r?utm_source=stocktwits&utm_medium=story_url
0 replies
Prady Oct 9, 3:04 AM
$BSX $JNJ JNJ will acquire this for 80+ by year end .
3 replies
JCJustCharting Oct 8, 9:53 PM
$SPY buy healthcare biotech that are profitable during red market $ABBV $LLY $JNJ
0 replies
Millionaire11 Oct 8, 7:12 PM
$CMPS $JNJ do it. We want $55 a share.
0 replies
pilobious Oct 8, 3:38 PM
$JNJ why the beatdown three days before an earnings release?
0 replies